Breaking News
March 19, 2018 - AcelRx Announces Receipt of Type A FDA Meeting Minutes and Plans to Resubmit the DSUVIA New Drug Application in Q2 2018
March 19, 2018 - Eye Docs Adopt EHRs Despite Reservations
March 19, 2018 - CRISPR enhances cancer immunotherapy
March 19, 2018 - Study finds first evidence of delayed aging among Americans
March 19, 2018 - Essential oils linked to abnormal breast development in boys
March 19, 2018 - ‘Tummy Tuck’ Relieved Postpartum Back Pain/Incontinence
March 19, 2018 - New biomarkers for neuroblastoma, a type of cancer in children
March 19, 2018 - Hookah Smoking Carries a Poisoning Risk
March 19, 2018 - Do Mood and Anxiety Affect MS Disability?
March 19, 2018 - Mean depth of ultrasonographic penetration greater in autism
March 19, 2018 - Platypus milk may help combat antibiotic resistance
March 19, 2018 - U.S. IDE study of THERMOCOOL SMARTTOUCH SF Catheter completes patient enrollment
March 18, 2018 - E-cigarette use exposes adolescents to potentially cancer-causing chemicals
March 18, 2018 - GOP Senator: Solve Opioid Crisis Through Community, Not Policy
March 18, 2018 - Why is ADHD more common in boys than girls?
March 18, 2018 - Measles alert after two passengers with the disease fly into US
March 18, 2018 - FDA looks to remove nicotine from cigarettes
March 18, 2018 - FDA moves to cut nicotine in cigarettes, helping smokers kick habit
March 18, 2018 - Athenex Announces Phase II Clinical Study Results for KX2-391 Ointment for the Treatment of Actinic Keratosis
March 18, 2018 - Surgery Tied to Better Outcomes in Kids with T2D
March 18, 2018 - Scientists use nanotechnology to detect molecular biomarker for osteoarthritis
March 18, 2018 - Research establishes use of chimeric cells as potential therapy for Duchenne muscular dystrophy
March 18, 2018 - Researcher working to develop improved endoscopic probe for colonoscopies
March 18, 2018 - Researchers develop way to sequence entire fetal genome by modifying prenatal testing method
March 18, 2018 - FDA Approves PDUFA Fee Waiver for Gimoti New Drug Application
March 18, 2018 - P2Y12 Tx Subsidy Yields Positive Response from Docs, Patients
March 18, 2018 - Are Proteins in Formula Linked to Type 1 Diabetes?
March 18, 2018 - Exercise does not seem to increase bone marrow edema in healthy people
March 18, 2018 - Researchers delineate architecture of nuclear pore complex in yeast cells
March 18, 2018 - ‘It’s Just Ghetto-izing People’: What We Heard This Week
March 18, 2018 - Alzheimer’s disease: Neuronal loss very limited
March 18, 2018 - Study reveals impact of intense, changing work schedules experienced by medical interns
March 18, 2018 - Jobs That Keep the Mind Sharp … Even Into Retirement
March 18, 2018 - Facial Scarring Improved with Botulinum Toxin
March 18, 2018 - Data detectives shift suspicions in Alzheimer’s to inside villain
March 18, 2018 - Shorter Preventive TB Tx Effective for HIV+ Patients
March 18, 2018 - New technique for identifying alcoholism puts treatment options at patients’ and providers’ fingertips
March 18, 2018 - Researchers uncover four microRNAs as potential biomarkers for atrial fibrillation
March 18, 2018 - IRX Therapeutics Announces Initiation of Phase 2 Clinical Trial of IRX-2 in Squamous Cervical or Vulvar Intraepithelial Neoplasia 3
March 18, 2018 - OncoBreak: Learning from Silence; ‘Rigged’ Drug System; NCCN Guidelines Questioned
March 18, 2018 - The coffee cannabis connection
March 18, 2018 - Novel centrifugal-flow pump for heart failure patients provides improved long-term outcomes
March 18, 2018 - U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation
March 18, 2018 - Cath Lab Recap: iFR vs FFR $$; Ridaforolimus-Eluting Stent
March 18, 2018 - Tree care workers need better training to handle dangers on the job, study finds
March 18, 2018 - Dementia patients do not undergo diagnostic evaluation at onset of disease, study finds
March 18, 2018 - Transplanting enhanced interneurons restores brain rhythms in mouse model of Alzheimer’s
March 18, 2018 - Gene Therapy Flops for Critical Limb Ischemia
March 17, 2018 - Study spotlights risks in anesthesiologist handoffs
March 17, 2018 - Verb fluency test may be useful tool for differential diagnosis of cognitive failure
March 17, 2018 - Health Tip: Suggestions to Improve Your Cholesterol
March 17, 2018 - Fructans Suspect in Non-Celiac Gluten Sensitivity
March 17, 2018 - Aspirin therapy appears safe before thyroid surgery
March 17, 2018 - Minimally invasive surgical device may one day provide lasting heart repair
March 17, 2018 - UIH and RaySearch enter into new partnership
March 17, 2018 - Is BMI Too Inexact? | Medpage Today
March 17, 2018 - Sleep apnea study finds male-female differences in cerebral cortex thickness, symptoms
March 17, 2018 - Leicester research could help identify people with asthma of different severities
March 17, 2018 - Biosense Webster enrolls and treats first AF patient in clinical study of new RF balloon catheter
March 17, 2018 - Participants in rogue herpes vaccine research take legal action
March 17, 2018 - Imara Doses First Patient in Phase 2a Clinical Trial of IMR-687 for Sickle Cell Disease
March 17, 2018 - AAP: Prevent Medication Errors by Improving Processes
March 17, 2018 - Severe sleep apnea during REM sleep tied to acute CV events
March 17, 2018 - Alzheimer’s disease also affects small blood vessels
March 17, 2018 - Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
March 17, 2018 - Switching Biologics in Psoriasis Care
March 17, 2018 - Polygenic risk score may identify alzheimer’s risk in younger populations
March 17, 2018 - Genetic heart mutations account for fewer sudden and unexplained infant deaths
March 17, 2018 - Clinical trial to test efficacy of stem cell transplants in stopping ALS muscle deterioration
March 17, 2018 - Researchers team up to improve life for children with microcephaly
March 17, 2018 - Health guide for young women regarding labiaplasty
March 17, 2018 - Inhaled Nitrite Flops as HFpEF Therapy
March 17, 2018 - California mental health tax providing services to needy in L.A. County, study finds
March 17, 2018 - Cancer survivors become fatigued more quickly than their peers, study finds
March 17, 2018 - Study finds common presence of nightmares among U.S. military personnel
March 17, 2018 - Yellow fever outbreak in Brazil necessitates vaccination for travelers
March 17, 2018 - Health Tip: Waist Size May Help Predict Heart Attack
March 17, 2018 - Low-Dose Combo Pill Successfully Takes Down High BP
March 17, 2018 - Most children with sickle cell anemia not receiving key medication to stay healthy
March 17, 2018 - YCC launches new Yale Center for Immuno-Oncology
Brachytherapy Boost Tops Surgery for Prostate Ca

Brachytherapy Boost Tops Surgery for Prostate Ca

image_pdfDownload PDFimage_print

Patients with a particularly aggressive form of prostate cancer treated with extremely dose-escalated external beam radiotherapy (EBRT) plus androgen deprivation therapy (ADT) achieved better clinical outcomes than those treated with radical prostatectomy, a retrospective study indicated.

EBRT plus brachytherapy was associated with significantly lower prostate cancer–specific mortality than either EBRT alone (cause-specific hazard ratio 0.41, P=0.002) or radical prostatectomy (HR 0.38, P=0.001), with a better adjusted 5-year prostate cancer–specific mortality rate (3%) compared with EBRT alone (13%) or radical prostatectomy (12%), reported Amar U. Kishan, MD, of the University of California Los Angeles, and colleagues in JAMA.

EBRT plus brachytherapy also yielded better adjusted 5-year incidence rates of distant metastasis (8%) compared with EBRT alone or radical prostatectomy (24% each), with a significantly lower rate of distant metastasis compared with EBRT alone (propensity-score-adjusted cause-specific HR 0.30, P<0.001) or radical prostatectomy (HR 0.27, P<0.001).

“I would present extremely dose-escalated radiotherapy as an option to all patients I see,” said Kishan in an email to MedPage Today. “The data, albeit retrospective, are compelling.”

This cohort study included 1,809 patients with Gleason score 9-10 prostate cancer treated from 2000 to 2013 at 12 tertiary centers.

Patients were grouped into three cohorts based on the type of definitive therapy received: extreme dose escalation of external beam radiotherapy (EBRT) plus a brachytherapy boost (n=436; median age 67.5), EBRT alone (n=734; median age 67.7), or radical prostatectomy (n=639; median age, 61). Prostate cancer–specific mortality was the primary endpoint.

ADT is generally recommended among patients receiving EBRT, but may be contraindicated for medical reasons — patients who did not receive ADT were not excluded.

Adjusted 7.5-year all-cause mortality rates were 10% with EBRT plus brachytherapy, 18% with EBRT alone, and 17% with radical prostatectomy. Within the first 7.5 years of follow-up, EBRT plus brachytherapy was associated with significantly lower all-cause mortality compared with EBRT alone (cause-specific HR 0.61, P=0.002) and radical prostatectomy (HR 0.66, P=0.03).

But these differences did not remain statistically significant beyond 7.5 years.

Use of EBRT plus brachytherapy declined over the years among the patients studied, mostly in favor of radical prostatectomy. From 2000 to 2005, 31% of patients received EBRT plus brachytherapy. This percentage dropped to 25% from 2006 to 2010 and to 15% from 2011 to 2013. During these same years, frequency of radical prostatectomy use rose from 24% to 53%.

“I would also stress that, should patients move forward with standard radiotherapy, they consider the importance of receiving at least high-dose radiation, along with a long duration of ADT,” said Kishan, noting that outcomes were better in the subgroup that received ADT.

“For patients receiving radical prostatectomy, early postoperative radiotherapy (potentially with ADT at that point), may be superior to just radical prostatectomy,” he said. “I think the important theme is that many patients with Gleason score 9-10 disease need a multimodality strategy that includes both intense local treatment and some form of systemic treatment.”

Some of the limitations of the study include its retrospective nature, though a randomized trial in this population would likely not be feasible due to the relative rarity of the disease, according the authors — only 7% to 10% of prostate cancer cases are Gleason score 9-10 on biopsy. Due to the aggressive nature of this disease, however, this comparative outcomes analysis was able to achieve statistical power within a contemporary treatment period.

Patient-reported outcomes or toxicity profiles by treatment type were not available for the researchers to analyze. In the ASCENDE-RT trial, EBRT plus brachytherapy resulted in poorer urinary and physical function as reported by patients compared with EBRT alone.

“This is an important point,” said Kishan. “Extremely dose-escalated radiotherapy may not be appropriate for patients with severe urinary symptoms, very large prostates or high-risk of bleeding that could make the brachytherapy procedure difficult.”

Other limitations of the study were a short median follow-up time, not all centers providing data on the three treatment modalities, and only 41% of EBRT-treated patients receiving both radiotherapy doses of 70 Gy or greater and ADT for a duration of 2 years or longer — suggesting a tolerance issue with the combination.

Kishan disclosed no relevant relationships with industry. Co-authors reported relationships with ViewRay, Soylent, Bayer, Astellas, Ferring, Dendreon, Blue Earth, GenomeDx, Augmenix, Janssen, Varian Systems, and Nanobiotix. One co-author was a Varian employee.


last updated

Tagged with:

About author

Related Articles